Long-term pulmonary consequences of respiratory distress syndrome in preterm infants treated with exogenous surfactant
- PMID: 8441104
- DOI: 10.1016/s0022-3476(05)83439-0
Long-term pulmonary consequences of respiratory distress syndrome in preterm infants treated with exogenous surfactant
Abstract
The pulmonary outcome for preterm infants 1 year after synthetic surfactant replacement for respiratory distress syndrome was assessed by examining their pulmonary status and the results of pulmonary function tests. A total of 47 infants were followed: 13 infants mean +/- SD: birth weight, 1960 +/- 616 gm; gestation, 32 +/- 1.1 weeks) had been assigned to the placebo group and 34 (birth weight = 1890 +/- 530 gm; gestation = 32 +/- 2.5 weeks) to surfactant treatment. The infants were examined at 3 to 6 months of age (n = 45) and at 9 to 12 months of age (n = 36). There were no significant differences between the two groups in predisposing clinical conditions that would lead to chronic lung disease. The infants had similar patterns of growth, respiratory-related illness, and need for theophylline therapy, diuretic therapy, or both. None had hypoxemia by pulse oximetry. Mean (+/- SEM) values for pulmonary mechanics and energetics in surfactant-treated infants were significantly (p < 0.01) lower for total pulmonary resistance in late infancy (57.7 +/- 11.7 vs 35.3 +/- 4.6 cm H2O/L per second). Lower values (mean +/- SEM) of resistive work of breathing were also measured in the surfactant-treated group (60.7 +/- 12.0 vs 38.2 +/- 3.6 gm-cm/kg per breath). The dynamic pulmonary compliance values were in the low-normal range for both groups, and the mean (+/- SEM) peak-to-peak esophageal pressure values were elevated (11.47 +/- 2.26 cm H2O in the placebo group; 9.24 +/- 0.69 cm H2O in the surfactant group). Forced expiratory flow measurements in late infancy demonstrated significant (p < 0.01) improvement in expiratory reserves and reduced evidence of airflow obstruction in the surfactant-treated infants (peak flow (mean +/- SEM): 287.1 +/- 69 vs 396.9 +/- 27 ml/sec; forced expiratory flow (mean +/- SEM) at functional residual capacity: 56.3 +/- 7.5 vs 83.4 +/- 19.5 ml/sec). No significant differences in pulmonary functions were noted in early infancy. These data suggest that surfactant replacement for respiratory distress syndrome may be associated with beneficial long-term effects on the resistive airflow properties of larger preterm infants.
Similar articles
-
Postnatal changes in pulmonary mechanics and energetics of infants with respiratory distress syndrome following surfactant treatment.Biol Neonate. 2005;87(4):323-31. doi: 10.1159/000084880. Epub 2005 Jun 1. Biol Neonate. 2005. PMID: 15985755 Clinical Trial.
-
Pulmonary mechanics and energetics in preterm infants who had respiratory distress syndrome treated with synthetic surfactant.J Pediatr. 1992 Feb;120(2 Pt 2):S18-24. doi: 10.1016/s0022-3476(05)81228-4. J Pediatr. 1992. PMID: 1735846 Clinical Trial.
-
A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Vermont-Oxford Neonatal Network.Pediatrics. 1996 Jan;97(1):1-6. Pediatrics. 1996. PMID: 8545199 Clinical Trial.
-
Colfosceril palmitate. A review of the therapeutic efficacy and clinical tolerability of a synthetic surfactant preparation (Exosurf Neonatal) in neonatal respiratory distress syndrome.Drugs. 1991 Nov;42(5):877-94. doi: 10.2165/00003495-199142050-00009. Drugs. 1991. PMID: 1723378 Review.
-
Delayed compliance increase in infants with respiratory distress syndrome following synthetic surfactant.Pediatr Pulmonol. 1992 Dec;14(4):206-13. doi: 10.1002/ppul.1950140403. Pediatr Pulmonol. 1992. PMID: 1484754 Review.
Cited by
-
Delivery and performance of surfactant replacement therapies to treat pulmonary disorders.Ther Deliv. 2013 Aug;4(8):951-80. doi: 10.4155/tde.13.72. Ther Deliv. 2013. PMID: 23919474 Free PMC article. Review.
-
A risk-benefit assessment of natural and synthetic exogenous surfactants in the management of neonatal respiratory distress syndrome.Drug Saf. 1998 May;18(5):321-37. doi: 10.2165/00002018-199818050-00002. Drug Saf. 1998. PMID: 9589844
-
Pulmonary surfactant and COVID-19: A new synthesis.QRB Discov. 2022 Apr 22;3:e6. doi: 10.1017/qrd.2022.1. eCollection 2022. QRB Discov. 2022. PMID: 37564950 Free PMC article.
-
How best to capture the respiratory consequences of prematurity?Eur Respir Rev. 2018 Mar 14;27(147):170108. doi: 10.1183/16000617.0108-2017. Print 2018 Mar 31. Eur Respir Rev. 2018. PMID: 29540497 Free PMC article. Review.
-
Surfactant replacement therapy.Thorax. 1996 Nov;51(11):1137-54. doi: 10.1136/thx.51.11.1137. Thorax. 1996. PMID: 8958900 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical